Interim report 2026
Filed with HKEX · Stock code 2552 · · 61 pages · English
Earlier from Hua Medicine
- Hua Medicine Announces 2026 Interim Results
- Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
- Hua Medicine Announces 2025 Interim Results
- Hua Medicine Announces 2024 Annual Results
- Hua Medicine’s Leadership in Diabetes Treatment Recognized: CEO Dr. Li CHEN Awarded Prestigious C.C. Tan Life Science Industrialization Award
Later from Hua Medicine
- Notification letter to registered shareholders and reply form
- Notification letter to non-registered shareholders and request form
- Monthly Return of Equity Issuer on Movements in Securities
Follow Hua Medicine into a list and get an email when it puts out news.
Follow Hua Medicine